Search

IOM panel presses for new policies to spur research and development Thirty-five years after mammography screening demonstrated a 30 percent mortality reduction,[1] researchers are still searching for an ideal breast [...]

Reports on the concerns of urologists regarding the overuse of prostate specific antigen (PSA) testing in older men according to a survey. Breakdown of statistics; Influencing factors; Implications.

Reports on the potential uses of telomerase as a marker to discriminate aggressive from indolent prostate cancers. Telomerase as the enzyme that maintains chromosome ends or telomeres; Reactivation of telomerase and cancer progression.

Focuses on the use of reverse transcriptase-polymerase chain reaction (RT-PCR) assays to detect prostate cancer metastases. Centers researching the assay; Criticisms of the test.

Discusses various biological techniques as modern innovations in the diagnosis and treatment of prostate cancer revealed by researchers attending the American Urological Association's (AUA) 90th annual meeting. Determining prognosis; Selecting the best therapeutic method; Uses of the prostate-specific membrane (PSM) antigen; Differences in PSM-positivity; Uses of the P53 suppressor gene.

Reports that percent positive biopsies is an independent predictive variable that should be factored into nomograms for prostate cancer, according to researcher Gary D. Grossfeld. Details of Grossfeld's study of the CaPSURE registry of prostate cancer patients presented during the American Society of Clinical Oncology's year 2001 meeting held in San Francisco, California.

Reports on a new computerized imaging system which improves prostate cancer staging. Characterization of microvessel density in prostate cancer.

Reports on the successful detection, through a reverse-transcriptase polymerase-chain reaction (RT-PCR) assay, of prostate cancer metastases in pelvic lymph nodes considered free of metastases based on conventional pathology at the time of surgery. Development of the assay by Robert Edelstein, a urologist at the Boston University School of Medicine.

Reports on increasing doubts concerning the value of reverse-transcriptase polymerase-chain reaction (RT-PCR) assays for prostate-specific antigen (PSA) expressed during the 1996 annual meeting of the American Urological Association held in Orlando, Florida. Inconsistency in test results; Lack of accuracy for preoperative staging and follow-up; Comments from urologists skeptic of RT-PCR assays.

Reports on the finding of researchers from Johns Hopkins on a way to detect and harvest prostate cancer cells from the bloodstream. Description of the technique; Implication of the research finding on the development of prostate cancer vaccines; Method for isolating prostate cancer cells.

Reports on a study led by Michael Brawer which found the IMx prostate-specific antigen (PSA) assay have a tendency to give lower values that the Tandem E assay. Marked discrepancies between the assays in patients with known cancers.

Reports on the status of monoclonal antibody scanning technology as a tool for the diagnosis of prostate cancer. Theoretical foundation of the technique; Linkage of the monoclonal antibody Cyt-356 to radiolabeled indium which binds to an antigen; Ability to look for sites of metastasis in prostatic cancer; Difficulty in interpretation of the scanning method.

Reports that researchers has recommended the use of a sinogram as a radiologic study to diagnose urachal abnormalities. Study of cases of urachal anomalies by Bartley Cilento and Anthony Atala; Importance of surgical excision of a small part of the bladder cuff; Differentiation of a patent urachus from a urachal sinus.

Reports on the use of pretreatment alkaline phosphatase as a predictor of duration of response to treatment and survival in metastatic prostrate cancer as discussed by Dr. Joseph A. Smith during the American Urological Association 1995 meeting. Comparison with bone scans; Determination of the need for aggressive treatment.

Discusses the importance of measuring the percent free prostate-specific antigen (PSA) levels in detecting prostate cancer in men according to Washington University School of Medicine, St Louis division of urology professor and chair Dr. William Catalona. Differentiating benign conditions from cancers; Cutting false-positive results; Limitations.